Alcon Ag · SIX:ALC
Alcon — JP Morgan Healthcare Conference 2020
22 slides from Alcon's conference presentation, Jan 14, 2020
Slide 1: Investor Presentation JP Morgan Conference
Investor Presentation JP Morgan Conference January 14, 2020 San Francisco 1
Slide 2: Legal Disclaimers
Legal Disclaimers Forward-Looking Statements This document contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward- looking statements can be identified by words such as: “anticipate,” “inte
Slide 3: Alcon is the largest global player in eye care
Alcon is the largest global player in eye care $7b #1 or #2 sales in all categories within favorable market trends with significant opportunities growing eye care Surgical & Vision Care device leader to grow and expand $24b $10b $14b market Surgical market Consumables, implantables Vision care marke
Slide 4: Sizeable opportunities with substantial unmet medical need
Sizeable opportunities with substantial unmet medical need could be saved with 80 $102b % of visual impairment is preventable or curable1 appropriate eye care services1 People: 153 million 1.7 billion 352 million 20 million 93 million 67 million with uncorrected have live with are blind have live wi
Slide 5: Favorable megatrends underpin strong market potential
Favorable megatrends underpin strong market potential Myopia prevalence is Aging population Increasing wealth Innovation improving the growing; increased screen with growing eye care and growth from quality of eye care time and mobile device needs emerging economies use is impacting vision Populatio
Slide 6: Leader in the markets we serve
Leader in the markets we serve #1 or #2 in all product categories Surgical ($4.0b) Vision Care ($3.1b) Implantables Consumables Equipment / Other Contact Lenses Ocular Health MARKET POSITION # 1 # 1 # 1 # 2 # 1 KEY BRANDS 2018 SALES $1.2b $2.2b $0.6b $1.9b $1.2b Table represents a sampling of key pr
Slide 7: Investing for long term growth
Investing for long term growth 7
Slide 8: Advancing to the next phase of growth
Advancing to the next phase of growth 2016-2017 2018-2020 2021+ Fix the Execute the Deliver growth plan leading-edge solutions Foundation Invest behind key growth drivers Accelerate innovation Prepare to stand-up new Alcon Invest in our innovation pipeline Expand markets & adjacencies New business m
Slide 9: Growing top line and expanding core operating margin
Growing top line and expanding core operating margin 2023 Financial Outlook 5.0% 18% 4.0% Sales growth projections: 17% Mid-single digit CORE OPERATING MARGIN 3.0% (% CAGR 2018-2023) (constant currency) 16% SALES GROWTH 5% 5% 2.0% 3% 15% 1.0% 14% Core operating margin1 0.0% projections: -1% Low-to-m
Slide 10: Investing in our R&D pipeline
Investing in our R&D pipeline Significant near-term portfolio advancements, as well as longer-term innovation R&D EXPENSE Portfolio Advancements • Improved contact lens & IOL materials NOVEL LIFE CYCLE MGT • Automated manufacturing INNOVATION 11% • New equipment platforms 21% LINE EXTENSIONS 9% • In
Slide 11: Investing in our near-term expected product launches
Investing in our near-term expected product launches 100+ active projects in the pipeline 12 months 2020-2021 Key Products SURGICAL VISION CARE PANOPTIX trifocal PRECISION1 sphere daily lens VIVITY non-diffractive IOL SYSTANE preservative free CLAREON with AUTONOME PATADAY OTC allergy drops ARGOS bi
Slide 12: PANOPTIX
PANOPTIX FIRST AND ONLY TRIFOCAL LENS IN THE US IMPLANTABLES MARKET (Last 12 months) PANOPTIX provides 96% spectacle independence and 29% exceptional visual performance at every meaningful distance1 AT-IOLs One of the most successful launches in Alcon’s history MONOFOCALS $3b Market share oppo
Slide 13: VIVITY
VIVITY FIRST AND ONLY NON-DIFFRACTIVE PC-IOL + MONOFOCAL VISUAL PROFILE Excellent near and intermediate acuity versus monofocals % of Patients Reporting with Good/Very Good Ideal for patients not suitable for PANOPTIX seeking PC-IOL Vision Without Spectacles in Bright Light1 performance: Post-LA
Slide 14: PRECISION1
PRECISION1 THE LENS FOR NEW WEARERS TO START IN AND STAY IN GLOBAL CONTACT LENS MARKET (Last 12 months) Strong double digit growth in daily SiHy contact lenses Preferential study finds 5x more customers prefer REUSABLE PRECISION1 over the leading daily lens1 Wearers rate PRECISION1 better than
Slide 15: DAILIES TOTAL1 TORIC PRECISION1
DAILIES TOTAL1 TORIC PRECISION1 GLOBAL CONTACT LENS MARKET (Last 12 months) TORIC The fastest growing market segment is daily SiHy 23% Bringing the superior surface lens technology of DT1 and P1 into the toric market, launching late 2020 $9b MULTI-FOCAL SPHERE 65% of contact lens drop-outs hav
Slide 16: PATADAY
PATADAY Addressing eye care needs in allergy U.S. ALLERGY MARKET 2018 66 million Americans suffer from ocular allergies, with REDNESS OTC ALLERGY only 10% using eye drops1,2 RELIEF 17% Pataday contains the #1 eye allergy itch relief ingredient3 for ocular allergies, with a long heritage in the p
Slide 17: The future of eye care
The future of eye care 17
Slide 18: Digital Health Solutions
Digital Health Solutions SMART Cataract Artificial Intelligence & Optimization All in One Diagnostics Digitally Assisted Surgery replaces multiple current with the most advanced In-office devices pre & post-op operating room equipment 18
Slide 19: Innovating future contact lens platforms
Innovating future contact lens platforms Surface chemistry GREATER: Comfort Visual acuity Convenience Access 19
Slide 20: Summary
Summary Global leader in eye care serving attractive end markets Delivering sustainable growth and profitability Investing in our pipeline and product launches to accelerate growth Leveraging Alcon’s industry leadership to expand markets and address customer unmet needs 20
Slide 21: To See Brilliantly. and Live Brilliantly.
To See Brilliantly. and Live Brilliantly. 21 Business Use Only | 21
Slide 22: Official Sponsor of 20/20
Official Sponsor of 20/20 See Brilliantly